| 題庫總數：15 | ||
| 是非題：0 | ||
| 選擇題：15 (A：5、B：0、C：1、D：9) | ||
| 多選題：0 | ||
| roddayeye整理 | ||
| Q | 關於多重抗藥性菌種院內感染之影響 ，下列何者正確? | |
| 1.延長住院日數，造成殘疾、失去生命 | ||
| 2.關閉病房、院譽受損、負法律責任 | ||
| 3.增加工作量，增加感染之危險性 | ||
| v | 4.以上皆是 || | |
| Q | 關於CRE(carbapenem-Resistant enterobacteriaceae)的Identification，下列何者有誤? | |
| v | 1.Clinical Laboratory and Standards Institute (CLSI) 為了偵測carbapenemase 的存在,已將MIC Breakpoints for Carbapenems提高 | |
| 2.Identification of E. coli or K. pneumoniae with overt resistance to any of the carbapenems should raise suspicion that it may be harboring a carbapenemase enzyme. | ||
| 3.臺灣的CDC有做CRE的抗藥性檢測 | ||
| 4.NDM-1腸道菌感染症是法定傳染病 || | ||
| Q | Infection Control for CRE (carbapenem-resistant enterobacteriaceae) ，下列何者有誤? | |
| v | 1.Hospitalized patients infected or colonized with carbapenemase-producing bacteria should be placed on airborn precautions | |
| 2.Hand hygiene | ||
| 3.Antimicrobial stewardship | ||
| 4.Screening high-risk patients to detect rectal colonization. || | ||
| Q | 關於 Antimicrobial Therapy for CRE (carbapenem-resistant enterobacteriaceae) | |
| 1.The optimal treatment of infection due to carbapenemase-producing organisms is uncertain | ||
| 2.CRE 會 confers resistance to all penicillins, cephalosporins, and carbapenems | ||
| v | 3.For severe infections, monotherapy 較combination antimicrobial therapy with two or more agents 效果 為佳 | |
| 4.Emergence of resistance during monotherapy || | ||
| Q | CRE(carbapenem-Resistantenterobacteriaceae)的transmission，下列何者有誤? | |
| 1.Enterobacteriaceae，which harbor carbopenem-encoding genes，can spread from person to person | ||
| 2.Cross-infection within &outside of health system | ||
| 3.Health workers 的手也是主要傳播媒介 | ||
| v | 4.CRE因帶有mobile genetic elements，不會wide spread transmission to other isolates & genera of bacteria || | |
| Q | 關于NDM(New Delhi metallo-β-lactamase)何者不正確? | |
| v | 1.Genetic element為chromosome | |
| 2.Medical tourism 造成全球的擴散 | ||
| 3.Widespread nonprescription use of antibiotics in India造成huge selection pressure | ||
| 4.Most common in E coli || | ||
| Q | 細菌對carbapenem有抗藥性的機制，下列何者不是？ | |
| 1.Loss of porins | ||
| 2.β-lactamase | ||
| 3.Overexpression of efflux pump | ||
| v | 4.Target mutations || | |
| Q | 下列何者carbapenemase在USA最常見 | |
| v | 1.KPC (Klebsiella pneumoniae carbapenemase) | |
| 2.NDM (New Delhi metallo-β-lactamase) | ||
| 3.Oxacillinase | ||
| 4.Amp C-like || | ||
| Q | 關於CRE(carbapenem-resistant enterobacteriaceae)的臨床表現，下列何者有誤? | |
| 1.Asymptomatic colonization | ||
| 2.Outbreaks due to hospital-based clonal spread | ||
| 3.Central venous catheter infections. | ||
| v | 4.以上皆非 || | |
| Q | 下列何種情況 應考慮對病人應進行CRE (carbapenem-resistant enterobacteriaceae)主動篩檢? | |
| 1.經調查後確定院內高風險區域 | ||
| 2.於48小時內來自高風險區域（如：長照機構或已證實有CRE院內群突發醫院）之入院病人。 | ||
| 3.病人須移轉至院內高風險區域（如：ICU）時。 | ||
| v | 4.以上皆是 | |
| Q | 關於預防多重抗藥性菌種在病房傳播，下列何者有誤? | |
| v | 1.病人在單位間互轉，不用先告知是否為多重抗藥性菌種 | |
| 2.優先考慮將多重抗藥性菌種病人安置在單人病房 | ||
| 3.將帶有相同多重抗藥性微生物的病人，集中照護 | ||
| 4.不建議將帶有多重抗藥性菌種病人安置於高傳染風險病人旁 || | ||
| Q | 關於多重抗藥性菌種發生的經過 ，下列何者正確? | |
| 1.在自然界中,原本就有抗藥性菌種存在 | ||
| 2.使用抗生素 ,除了殺死病菌, 也會破壞體內正常的菌種, 而使抗藥性菌種有機會增長. | ||
| 3.抗藥性菌種會將抗藥性基因傳播給其他非抗藥性菌種 | ||
| v | 4.以上皆是 || | |
| Q | 關於多重抗藥性菌種的院內感染管制措施 ，下列何者不正確? | |
| 1.Hand hygiene | ||
| 2.Standard and contact precautions (e.g., gowns, gloves) | ||
| 3.Cohorting of patients and staff, | ||
| v | 4.以上皆不正確 || | |
| Q | 關于KPC(Klebsiella pneumoniae carbapenemase)，何者有誤? | |
| 1.Higher incidence in long-term care facilities than in acute care hospitals in U.S.A | ||
| 2.會造成hospital outbreak | ||
| 3.Transmissible plasmids | ||
| v | 4.Can not transmitted from klebsiella to other genera || | |
| Q | Factors of antibiotic resistance，包括 | |
| 1.Aging population | ||
| 2.Chronic disease | ||
| 3.Invasive medical treatment | ||
| v | 4.以上皆是 || | |
文章標籤
全站熱搜
留言列表